BF Biosciences Limited
By PSX Investors Zone · Updated October 21, 2026
BF Biosciences Limited (BFBIO) is a Pakistan Stock Exchange-listed pharmaceutical company engaged in developing, manufacturing, marketing and distributing pharmaceutical products. It is an 80:20 joint venture between Ferozsons Laboratories Limited and Argentina's Bagó Group. In FY2026, the company reported revenue of Rs.9.46 billion and profit after tax of Rs.632.13 million, reflecting strong year-on-year growth. BFBIO was classified as Shariah-compliant in the PSX screening effective May 29, 2026. Investors should review its latest financial reports, expansion spending, regulatory developments and current Shariah status before making investment decisions.
Company Overview
BF Biosciences Limited (BFBIO) is a Pakistani pharmaceutical company involved in importing, manufacturing, marketing and distributing pharmaceutical products. The company operates in the healthcare industry, where product quality, regulatory compliance, manufacturing capacity and research capabilities are important business considerations.
BF Biosciences was incorporated in 2006 and is an 80:20 joint venture between Ferozsons Laboratories Limited and Argentina's Bagó Group. It was listed on the Pakistan Stock Exchange on October 21, 2024.
The company's operations include pharmaceutical manufacturing and the development of specialized therapies. Its expansion projects have included manufacturing lines for injectable products.
Official sources:
Latest Annual Financial Performance
For the financial year ended June 30, 2026, the company's reported financial results were:
| Financial metric | FY2026 | FY2025 |
|---|---|---|
| Net revenue | Rs.9.461 billion | Rs.5.837 billion |
| Gross profit | Rs.4.088 billion | Rs.2.288 billion |
| Profit before tax | Rs.1.067 billion | Rs.723.74 million |
| Profit after tax | Rs.632.13 million | Rs.447.15 million |
Source: FY2026 financial results announcement
Revenue increased by approximately 62% and profit after tax by approximately 41% year over year. These results indicate growth in the company's reported business, although investors should also examine cash generation, capital expenditure, finance costs and working-capital requirements.
The board did not recommend a cash dividend for FY2026, citing continuing expansion and investment requirements. Investors should consult the official annual financial statements and PSX announcement for the complete results and any subsequent decisions.
Shariah Compliance Status
BF Biosciences Limited was classified as Shariah-compliant in the PSX screening effective May 29, 2026, based on accounts to December 31, 2025.
| Screening measure | Reported ratio |
|---|---|
| Debt to total assets | 18.67% |
| Non-compliant investments to total assets | 13.26% |
| Non-compliant income to revenue | 1.23% |
| Illiquid assets to total assets | 70.83% |
Source: Official PSX Shariah screening notice
These figures apply to the stated screening period and should not be represented as current financial ratios without an updated calculation. Shariah status can change after subsequent reviews. Check the latest official PSX eligible-scrip list before publishing or relying on the classification.
Risk Warning: PSX Regulatory Status
The PSX company profile displays a Risk Warning Alert stating that the company is in continuous violation of specified PSX regulatory clauses and may face suspension of trading or delisting.
Investors should check the latest PSX notices to understand the current status and any remedial steps or regulatory decisions. The alert should not be omitted from the company profile while it remains displayed on the official PSX page.
Source: Official PSX company profile — BFBIO
What Investors Should Monitor
- Revenue and earnings growth: Check whether sales growth translates into sustainable profits and cash flow.
- Expansion expenditure: New manufacturing capacity may support future growth but can require substantial investment.
- Regulatory compliance: Pharmaceutical manufacturing and product sales depend on applicable approvals and quality standards.
- Product portfolio: Assess the company's product mix, market demand and competitive position.
- Working capital: Review receivables, inventory, operating cash flow and financing requirements.
- PSX regulatory notices: Monitor the Risk Warning Alert and any subsequent exchange announcements.
- Shariah screening: Verify the latest official status before making a Shariah-based investment decision.
Frequently Asked Questions
What is the PSX symbol of BF Biosciences Limited?
The company's ordinary shares trade under the symbol BFBIO on the Pakistan Stock Exchange.
What does BF Biosciences Limited do?
It develops, manufactures, markets and distributes pharmaceutical products.
Is BF Biosciences Limited Shariah-compliant?
It was classified as compliant in the PSX screening effective May 29, 2026, using accounts to December 31, 2025. Investors should verify the latest official screening before investing.
Did BFBIO make a profit in FY2026?
Yes. The company reported profit after tax of approximately Rs.632.13 million for the year ended June 30, 2026, compared with approximately Rs.447.15 million in FY2025.
Did BFBIO announce a dividend for FY2026?
The board did not recommend a cash dividend for FY2026. Check subsequent official disclosures for any changes.
What risk alert appears on the PSX profile?
The PSX profile displays a warning about continuous regulatory violations and the possibility of suspension or delisting. Investors should review the latest exchange notices for details.
Disclaimer
This profile is provided for educational and informational purposes only. It is not a recommendation to buy or sell BFBIO shares and does not guarantee returns. Financial results, regulatory status and Shariah classifications may change. Always review the latest official PSX disclosures, company financial statements and Shariah screening before making an investment decision.
This profile is for educational purposes and is not a recommendation to buy or sell any security.